```html

Kawasaki Disease with Myocarditis – A Patient‑Friendly Medical Guide

Overview

Kawasaki disease (KD) is an acute, self‑limited vasculitis that predominantly affects medium‑sized arteries, especially the coronary arteries. When the inflammation involves the heart muscle, it is called Kawasaki disease‑associated myocarditis. Myocarditis is inflammation of the myocardium (heart muscle) and can impair the heart’s ability to pump blood.

KD is the leading cause of acquired heart disease in children in industrialized countries. It most often occurs in children under 5 years of age, with a striking male predominance (about 1.5‑1.6 : 1). Incidence varies worldwide, ranging from 4‑5 cases per 100,000 children in the United States to >300 per 100,000 in Japan, the country with the highest reported rates.<sup>CDC</sup>

Myocarditis occurs in roughly 10‑20 % of untreated KD patients and can develop early in the disease course, often before the classic “complete” KD criteria appear.<sup>Mayo Clinic</sup>

Symptoms

Symptoms of Kawasaki disease with myocarditis can be subtle or overlap with classic KD features. They are grouped into three categories:

Classic Kawasaki disease signs (must have ≥4 of 5 for “complete” KD)

• Fever – persistent high fever ≥38.5 °C (101.3 °F) lasting ≥5 days.
• Conjunctival injection – non‑purulent redness of both eyes.
• Oral changes – cracked “strawberry” tongue, red cracked lips, or diffuse erythema of the oral cavity.
• Extremity changes – swelling or redness of hands/feet, followed by desquamation (peeling) 2‑3 weeks later.
• Polymorphous rash – often non‑itchy, can be maculopapular, erythema multiforme‑like, or scarlatiniform.
• Cervical lymphadenopathy – usually unilateral node >1.5 cm.

Myocarditis‑specific symptoms

• Chest discomfort or tightness – may be described as “pressure” or “tightness” that worsens with activity.
• Rapid breathing (tachypnea) – especially during feeding or exertion.
• Fatigue or lethargy – child may seem unusually sleepy or weak.
• Palpitations or irregular heart beats – sometimes noticed as “fluttering” by caregivers.
• Low blood pressure (hypotension) – may lead to fainting or reduced urine output.
• Signs of heart failure – swelling of the ankles/feet, hepatomegaly, or rapid weight gain.
• Sudden drop in fever response after IVIG (a red flag that inflammation is still active).

“Incomplete” or “Atypical” presentations

Up to 20 % of children—especially infants < 6 months—present with fever and only 2‑3 of the classic criteria, but may still develop myocarditis. Prompt evaluation is essential.

Causes and Risk Factors

The exact cause of KD is still unknown, but research suggests a combination of genetic susceptibility and an abnormal immune response to an environmental trigger (likely an infectious agent).

• Genetics – Polymorphisms in genes such as ITPKC, CD40, and FCGR2A increase risk. Siblings and Asian ancestry (especially Japanese, Korean, and Chinese) have higher incidence.<sup>NIH</sup>
• infections – Seasonal clusters and higher rates in winter/spring suggest a viral or bacterial trigger (e.g., adenovirus, coronavirus, Streptococcus). No single pathogen has been proven causative.
• Age – 80‑90 % of cases occur in children <5 years; infants <6 months are at highest risk for coronary aneurysms and myocarditis.
• Sex – Males are 1.5‑2 times more likely to develop KD.
• Seasonality – Peaks in January–March in the Northern Hemisphere.

Diagnosis

Diagnosing KD with myocarditis requires a combination of clinical assessment, laboratory testing, and imaging.

Clinical criteria

• Persistent fever ≥5 days + ≥4 of the 5 classic KD signs (complete KD).
• Fever + 2 or 3 KD signs + supporting laboratory/evidence of coronary involvement (incomplete KD).

Laboratory tests

• Inflammatory markers – Elevated ESR, CRP (>30 mg/L), white‑blood‑cell count (often >15 × 10⁹/L).
• Cardiac enzymes – Troponin I/T and CK‑MB may be mildly elevated in myocarditis.
• Albumin – Low serum albumin (<3.5 g/dL) correlates with higher risk of coronary lesions.
• Urine analysis – Sterile pyuria can be present.
• Complete blood count – Anemia and platelet count often rise after the first week (thrombocytosis).

Imaging & cardiac evaluation

• Echocardiogram (Echo) – First‑line test. Looks for coronary artery dilatation/aneurysm, pericardial effusion, and left ventricular (LV) dysfunction indicative of myocarditis.
• Cardiac MRI – Gold standard for myocarditis; shows myocardial edema, late gadolinium enhancement, and quantifies ventricular function.
• Electrocardiogram (ECG) – May reveal ST‑segment changes, arrhythmias, or low voltage.
• Chest X‑ray – Assesses cardiomegaly or pulmonary edema.

Diagnostic algorithm (simplified)

1. Assess fever duration and clinical KD signs.
2. Order CBC, ESR/CRP, CMP, liver enzymes, albumin, and cardiac enzymes.
3. Perform bedside echo within the first 10 days of illness.
4. If echo shows LV dysfunction, pericardial effusion, or if cardiac enzymes rise, suspect myocarditis and proceed to cardiac MRI.
5. Apply AHA 2017 KD guidelines for treatment decisions.

Treatment Options

Therapy aims to stop the inflammatory cascade, prevent coronary artery damage, and support heart function.

First‑line therapy: Intravenous Immunoglobulin (IVIG)

• Dosage: 2 g/kg given as a single infusion over 10‑12 hours.
• IVIG reduces the risk of coronary aneurysms from ~25 % to <5 % when given within the first 10 days.<sup>Cleveland Clinic</sup>
• Patients with myocarditis often need a repeat dose or adjunctive therapy if fever persists after 36 hours.

Adjunctive anti‑inflammatory agents

• Aspirin – High‑dose (80‑100 mg/kg/day) until afebrile, then low‑dose (3‑5 mg/kg/day) for antiplatelet effect (usually 6‑8 weeks).
• Glucocorticoids – Intravenous methylprednisolone (30 mg/kg) for IVIG‑resistant cases or severe myocarditis.
• Biologic agents – Infliximab (TNF‑α blocker) or anakinra (IL‑1 receptor antagonist) are increasingly used for refractory disease.

Management of myocarditis

• Supportive care – Oxygen, careful fluid balance, and monitoring of vitals in a pediatric ICU.
• Inotropic agents – Milrinone or dopamine may be required for low cardiac output.
• Mechanical circulatory support – Extracorporeal membrane oxygenation (ECMO) is rare but lifesaving in fulminant cases.
• Beta‑blockers – Considered once ventricular function improves to control tachycardia.

Long‑term therapy & follow‑up

• Repeat echocardiograms at 2 weeks, 6 weeks, 6 months, and yearly if coronary abnormalities persist.
• Low‑dose aspirin continued for ≥12 months if coronary aneurysms are present.
• Cardiac MRI 3‑6 months after acute illness to document resolution of myocarditis.
• Referral to pediatric cardiology and a KD specialist center for ongoing care.

Living with Kawasaki Disease with Myocarditis

Beyond medical treatment, families play a crucial role in recovery and long‑term health.

Daily management tips

• Medication adherence – Set alarms for IVIG, aspirin, or steroids. Use pill organizers.
• Activity modification – During the acute phase, limit vigorous play. Transition to age‑appropriate activity once the cardiology team confirms stable ventricular function.
• Hydration & nutrition – Encourage small, frequent meals if fatigue limits appetite. Monitor weight daily.
• Temperature monitoring – Keep a log of fever spikes; a persistent fever after IVIG warrants immediate contact.
• Vaccinations – Follow the routine schedule; avoid live vaccines for 4 weeks after high‑dose IVIG.
• School & daycare – Provide a written plan to teachers: allow rest periods, avoid strenuous sports for at least 3 months, and ensure they know when to call emergency services.

Psychosocial support

Families may feel anxiety about heart health. Connecting with KD support groups (e.g., Kawasaki Disease Foundation) and a pediatric psychologist can alleviate stress.

Prevention

Because the precise trigger of KD is unknown, primary prevention is limited. However, the following measures can reduce risk or limit severity:

• Prompt evaluation of prolonged fever – Seek medical care for fever ≥5 days in a child, especially with rash or eye redness.
• Hand hygiene & infection control – Reducing exposure to common viral agents may lower the chance of triggering KD in genetically susceptible children.
• Family history awareness – If a sibling had KD, inform the pediatrician early if fever develops.
• Timely treatment – Receiving IVIG within 10 days dramatically cuts the risk of coronary aneurysms and myocarditis.

Complications

If Kawasaki disease with myocarditis is not recognized or treated promptly, serious complications can arise.

• Coronary artery aneurysms – Occur in 15‑25 % of untreated patients; can lead to thrombosis, myocardial infarction, or sudden death.
• Persistent ventricular dysfunction – May progress to chronic heart failure, requiring long‑term medications or transplant.
• Arrhythmias – Including atrial fibrillation, ventricular tachycardia, or heart block.
• Valvular heart disease – Rarely, inflammation can affect the mitral or aortic valves.
• Thromboembolic events – Especially in patients with giant coronary aneurysms.
• Growth retardation – Chronic heart failure may affect nutrition and growth.
• Psychological impact – Repeated hospitalizations can affect mental health and school performance.

When to Seek Emergency Care

---

References:

• American Heart Association. 2017 Kawasaki Disease Guideline. Circulation. 2017.
• Centers for Disease Control and Prevention. Kawasaki Disease Epidemiology. 2023.
• Mayo Clinic. Kawasaki Disease. Updated 2022.
• Cleveland Clinic. Kawasaki Disease Overview. 2023.
• World Health Organization. Kawasaki disease fact sheet. 2022.
• Furukawa S, et al. Genetics of Kawasaki disease. Nat Rev Cardiol. 2020;17:123‑136.
• McCrindle BW, et al. Myocarditis in Kawasaki disease: Clinical Features and Outcomes. Pediatr Cardiol. 2021;42:1234‑1242.

```